149 related articles for article (PubMed ID: 10086328)
1. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins.
Tateishi T; Watanabe M; Moriya H; Yamaguchi S; Sato T; Kobayashi S
Biochem Pharmacol; 1999 Apr; 57(8):935-9. PubMed ID: 10086328
[TBL] [Abstract][Full Text] [Related]
2. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
5. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
7. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
8. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations.
Yamazaki H; Okayama A; Imai N; Guengerich FP; Shimizu M
Xenobiotica; 2006 Dec; 36(12):1201-9. PubMed ID: 17162467
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
11. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.
Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M
Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064
[TBL] [Abstract][Full Text] [Related]
12. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
14. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Ando Y; Tateishi T; Sekido Y; Yamamoto T; Satoh T; Hasegawa Y; Kobayashi S; Katsumata Y; Shimokata K; Saito H
J Natl Cancer Inst; 1999 Sep; 91(18):1587-90. PubMed ID: 10491442
[No Abstract] [Full Text] [Related]
15. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
16. Developmental expression of the major human hepatic CYP3A enzymes.
Stevens JC; Hines RN; Gu C; Koukouritaki SB; Manro JR; Tandler PJ; Zaya MJ
J Pharmacol Exp Ther; 2003 Nov; 307(2):573-82. PubMed ID: 12975492
[TBL] [Abstract][Full Text] [Related]
17. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
18. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
19. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
20. The genetic determinants of the CYP3A5 polymorphism.
Hustert E; Haberl M; Burk O; Wolbold R; He YQ; Klein K; Nuessler AC; Neuhaus P; Klattig J; Eiselt R; Koch I; Zibat A; Brockmöller J; Halpert JR; Zanger UM; Wojnowski L
Pharmacogenetics; 2001 Dec; 11(9):773-9. PubMed ID: 11740341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]